Enanta Pharmaceuticals (ENTA) Competitors $8.28 -0.38 (-4.39%) Closing price 04:00 PM EasternExtended Trading$8.28 0.00 (-0.06%) As of 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ENTA vs. NRIX, ABUS, OCS, SNDL, GHRS, TBPH, PROK, VIR, KURA, and KALVShould you be buying Enanta Pharmaceuticals stock or one of its competitors? The main competitors of Enanta Pharmaceuticals include Nurix Therapeutics (NRIX), Arbutus Biopharma (ABUS), Oculis (OCS), SNDL (SNDL), GH Research (GHRS), Theravance Biopharma (TBPH), ProKidney (PROK), Vir Biotechnology (VIR), Kura Oncology (KURA), and KalVista Pharmaceuticals (KALV). These companies are all part of the "pharmaceutical products" industry. Enanta Pharmaceuticals vs. Its Competitors Nurix Therapeutics Arbutus Biopharma Oculis SNDL GH Research Theravance Biopharma ProKidney Vir Biotechnology Kura Oncology KalVista Pharmaceuticals Nurix Therapeutics (NASDAQ:NRIX) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their media sentiment, earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations. Do institutionals & insiders hold more shares of NRIX or ENTA? 95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. 7.4% of Nurix Therapeutics shares are owned by insiders. Comparatively, 13.9% of Enanta Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Is NRIX or ENTA more profitable? Enanta Pharmaceuticals has a net margin of -141.98% compared to Nurix Therapeutics' net margin of -234.57%. Nurix Therapeutics' return on equity of -45.26% beat Enanta Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Nurix Therapeutics-234.57% -45.26% -34.71% Enanta Pharmaceuticals -141.98%-89.02%-27.28% Do analysts recommend NRIX or ENTA? Nurix Therapeutics presently has a consensus target price of $29.07, suggesting a potential upside of 221.59%. Enanta Pharmaceuticals has a consensus target price of $22.25, suggesting a potential upside of 168.72%. Given Nurix Therapeutics' higher probable upside, equities research analysts clearly believe Nurix Therapeutics is more favorable than Enanta Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nurix Therapeutics 0 Sell rating(s) 3 Hold rating(s) 12 Buy rating(s) 1 Strong Buy rating(s) 2.88Enanta Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility & risk, NRIX or ENTA? Nurix Therapeutics has a beta of 2.1, suggesting that its share price is 110% more volatile than the S&P 500. Comparatively, Enanta Pharmaceuticals has a beta of 0.84, suggesting that its share price is 16% less volatile than the S&P 500. Which has preferable earnings and valuation, NRIX or ENTA? Enanta Pharmaceuticals has higher revenue and earnings than Nurix Therapeutics. Nurix Therapeutics is trading at a lower price-to-earnings ratio than Enanta Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNurix Therapeutics$54.55M12.67-$193.57M-$2.61-3.46Enanta Pharmaceuticals$67.64M2.62-$116.04M-$4.32-1.92 Does the media favor NRIX or ENTA? In the previous week, Nurix Therapeutics had 3 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 8 mentions for Nurix Therapeutics and 5 mentions for Enanta Pharmaceuticals. Enanta Pharmaceuticals' average media sentiment score of 1.69 beat Nurix Therapeutics' score of 1.10 indicating that Enanta Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nurix Therapeutics 3 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Enanta Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive SummaryNurix Therapeutics and Enanta Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks. Get Enanta Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ENTA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ENTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENTA vs. The Competition Export to ExcelMetricEnanta PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$185.13M$2.84B$5.79B$10.15BDividend YieldN/A56.65%5.69%4.61%P/E Ratio-1.9223.5374.5925.92Price / Sales2.62534.57449.5483.33Price / CashN/A169.2537.0859.91Price / Book1.365.3712.156.29Net Income-$116.04M$32.95M$3.28B$270.85M7 Day Performance-6.44%1.31%0.98%3.36%1 Month Performance20.70%8.31%7.20%6.41%1 Year Performance-32.08%0.29%63.06%28.26% Enanta Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENTAEnanta Pharmaceuticals4.1772 of 5 stars$8.28-4.4%$22.25+168.7%-28.1%$185.13M$67.64M-1.92160NRIXNurix Therapeutics2.3862 of 5 stars$9.34-0.7%$28.87+209.1%-61.3%$714.04M$54.55M-3.58300News CoveragePositive NewsHigh Trading VolumeABUSArbutus Biopharma2.034 of 5 stars$3.71+1.1%$5.50+48.2%+7.5%$711.20M$6.17M-12.7990News CoveragePositive NewsOCSOculis3.3025 of 5 stars$16.13-1.3%$35.75+121.6%+43.5%$704.28M$780K-6.042Short Interest ↓SNDLSNDL3.8409 of 5 stars$2.68-0.4%$4.00+49.3%+15.5%$704.24M$671.81M-9.932,516Positive NewsGHRSGH Research2.5362 of 5 stars$13.50-2.5%$32.00+137.0%+53.3%$702.38MN/A-18.2410TBPHTheravance Biopharma3.4808 of 5 stars$13.88-0.6%$21.33+53.7%+69.1%$699.02M$64.38M57.83110News CoveragePositive NewsAnalyst ForecastShort Interest ↑PROKProKidney3.5424 of 5 stars$2.36-5.6%$6.25+164.8%+24.2%$694.51M$80K-4.143News CoveragePositive NewsVIRVir Biotechnology3.25 of 5 stars$4.94-2.0%$28.44+475.8%-33.2%$686.25M$74.21M-1.24580KURAKura Oncology4.3181 of 5 stars$7.90-2.1%$24.10+205.1%-55.6%$685.70M$53.88M-3.50130Positive NewsInsider TradeKALVKalVista Pharmaceuticals4.0313 of 5 stars$13.46-0.4%$26.29+95.3%+38.2%$677.57MN/A-3.65100Trending NewsEarnings ReportAnalyst ForecastInsider Trade Related Companies and Tools Related Companies NRIX Competitors ABUS Competitors OCS Competitors SNDL Competitors GHRS Competitors TBPH Competitors PROK Competitors VIR Competitors KURA Competitors KALV Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ENTA) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredDo NOT Day Trade (Do THIS instead)Forget day trading (especially in markets like these). Trade OVERNIGHT instead! I've uncovered a shockin...Monument Traders Alliance | SponsoredThe $17B signal no one expected…After SpaceX struck a $17 billion deal with EchoStar for a block of radio frequencies, tech analyst Jeff Brown...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enanta Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enanta Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
